NCT02716012 2025-03-10
OUTREACH
Mina Alpha Limited
Phase 1 Unknown
Clinical Trials
578 trialsNCT06270706 2024-06-12
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Pliant Therapeutics, Inc.
Phase 1 Unknown
NCT06061445 2024-04-12
Radiotherapy Combined With TKI and Anti-PD-1 Antibody for Stage IIIA Hepatocellular Carcinoma
Fujian Cancer Hospital
Phase NA Unknown
NCT06355700 2024-04-09
HELIO
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase NA Unknown
NCT04929015 2024-03-21
Peritoneal Carcinomatosis Leveraging ctDNA Guided Treatment in GI Cancer Study (PERICLES Study)
Rutgers, The State University of New Jersey
Phase NA Unknown
NCT05783570 2024-03-15
To Evaluate the Safety, Tolerability and Preliminary Efficacy of EU307
Eutilex
Phase 1 Unknown
NCT06304766 2024-03-13
OPTIMAL
Rigshospitalet, Denmark
Phase NA Unknown
NCT04780217 2024-03-04
Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors
ImmVira Pharma Co. Ltd
Phase 1/2 Unknown
NCT06285019 2024-02-29
Modified TOMOX-HAIC in Combination With Sintilimab and Bevacizumab Biosimilar for First-line Treatment of Advanced Hepatocellular Carcinoma
Fudan University
Phase 2 Unknown
NCT06075849 2024-02-23
Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent
Panolos Bioscience
Phase 1 Unknown
NCT05178043 2024-02-22
GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma
Suzhou Kintor Pharmaceutical Inc,
Phase 2 Unknown
NCT06210334 2024-02-20
HAI-TL
Eastern Hepatobiliary Surgery Hospital
Phase 2 Unknown
NCT06148155 2024-02-16
A Study of [68Ga]Ga-NOTA-RG2 PET Imaging in the Diagnosis of Hepatocellular Carcinoma
Huashan Hospital
Phase NA Unknown
NCT05842317 2024-02-09
Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC
Peking Union Medical College Hospital
Phase 1/2 Unknown
NCT04560894 2024-02-01
HCC
Sinocelltech Ltd.
Phase 2/3 Unknown
NCT06233981 2024-01-31
Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thrombosis
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Unknown
NCT05062837 2024-01-23
Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC
Guangxi Medical University
Phase 2/3 Unknown
NCT05711823 2024-01-23
Aprepitant Plus Granisetron and Dexamethasone for the Prevention of Vomiting in Patients With HAIC Therapy for HCC
Guangxi Medical University
Phase 3 Unknown
NCT05910970 2024-01-23
PREVENT-2
Guangxi Medical University
Phase 3 Unknown
NCT06182644 2024-01-22
FAPI
Guangdong Provincial People's Hospital
Phase NA Unknown
NCT04224480 2024-01-19
Longitudinal Immune-phenotyping of HCC Following MK-3475
National Cancer Centre, Singapore
Phase 1 Unknown
NCT05962450 2024-01-16
Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy
Beijing YouAn Hospital
Phase 2 Unknown
NCT05021250 2024-01-10
SBRT With DIBH for HCC After TACE and Lipiodol Marking
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase NA Unknown
NCT05185531 2024-01-05
Notable-HCC
Shandong Cancer Hospital and Institute
Phase 1 Unknown
NCT06144385 2024-01-02
A Phase 1, Single-arm, Open-label, Dose-escalation Study of JWATM204 as T Cell-targeted Immunotherapy in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase 1 Unknown
NCT05718882 2023-12-28
Lenvatinib Plus VIC-1911 in Lenvatinib-unresponsive or Lenvatinib-resistant HCC
RenJi Hospital
Phase NA Unknown
NCT06182865 2023-12-27
A Study of Ga-68 Dolacga to Evaluate Liver Reserve Function in Patients With HCC Before and After Proton Therapy
National Atomic Research Institute, Taiwan
Phase NA Unknown
NCT04422249 2023-12-26
A Study of Laparoscopic Middle Hepatic Vein Guidance and Traditional Anatomic Hemihepatectomy
Southwest Hospital, China
Phase NA Unknown
NCT05031949 2023-12-19
CCGLC-003
Tongji Hospital
Phase 1 Unknown
NCT05103007 2023-12-19
CCGLC-004
Tongji Hospital
Phase NA Unknown
NCT05533892 2023-12-19
CCGLC-007
Tongji Hospital
Phase 1 Unknown
NCT04559607 2023-12-18
TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar Carcinoma
Zhongda Hospital
Phase NA Unknown
NCT03839706 2023-12-06
PETMRIinHCC
University Health Network, Toronto
Phase NA Unknown
NCT03448757 2023-11-22
Determination of Autonomic Responses to the Exposure of Low Energy Electromagnetic Fields With Frequency Modulation in Patients With Advanced Hepatocellular Carcinoma and Healthy Individuals.
Hospital Sirio-Libanes
Phase NA Unknown
NCT05609448 2023-11-18
EMERITUS-2
Radboud University Medical Center
Phase NA Unknown
NCT06101758 2023-10-26
SARCOLIVER
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase NA Unknown
NCT06003673 2023-10-24
A Clinical Study of Tislelizumab Combined With TACE and Lenvatinib in the Neoadjuvant Treatment of Resectable HCC
First Affiliated Hospital of Fujian Medical University
Phase 4 Unknown
NCT06088459 2023-10-18
NWRD06 DNA Plasmid for HCC After Radical Resection
Newish Technology (Beijing) Co., Ltd.
Phase 1 Unknown
NCT06085976 2023-10-17
Efficacy and Safety of Octreotide in Laparoscopic Hepatectomy Surgery: Effect on Blood Loss, Need for Vasoactive Drugs, Transfusion Requirements.
Clinica Universidad de Navarra, Universidad de Navarra
Phase 2 Unknown
NCT05250843 2023-10-13
TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC
Third Affiliated Hospital, Sun Yat-Sen University
Phase 2/3 Unknown
NCT06065592 2023-10-06
CAT_PB
Lebanese University
Phase 1 Unknown
NCT05352646 2023-09-28
NewishT Cell Therapy for HCC With High Risk of Recurrence After Radical Resection
Newish Technology (Beijing) Co., Ltd.
Phase 1 Unknown
NCT05010434 2023-09-21
Sintilimab and Bevacizumab Combined With Radiotherapy for Advanced Hepatocellular Carcinoma
Sun Yat-sen University
Phase 2 Unknown
NCT06039280 2023-09-15
Comparison of Dexamethasone and N Acetylcysteine (NAC) Versus N Acetylcysteine (NAC) Alone in the Prevention of Post Embolization Syndrome in Patients With Hepatocellular Carcinoma Following Transarterial Chemoembolization.
Institute of Liver and Biliary Sciences, India
Phase NA Unknown
NCT06040177 2023-09-15
Efficacy and Safety of SBRT Combined With Cardonilizumab and Lenvastinib in the Treatment of Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
First Affiliated Hospital of Guangxi Medical University
Phase 1/2 Unknown
NCT06001567 2023-09-14
Avatrombopag for HCC Patients With Thrombocytopenia Who Intend to Undergo TACE and/or HAIC
Second Affiliated Hospital of Guangzhou Medical University
Phase 2 Unknown
NCT03447951 2023-09-13
OASES
Gongwin Biopharm Co., Ltd.
Phase 2 Unknown
NCT06031480 2023-09-11
FAITH
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT06029829 2023-09-08
The Clinical Significance of Peripheral Blood T Lymphocyte PD-1 Expression and T Cell Subset Distribution.
China Three Gorges University, Yichang, China
Phase 2 Unknown
NCT06023147 2023-09-07
A Real-world Study of the Short-term Efficacy and Safety of E-TACE in Patients With Hepatocellular Carcinoma (HCC)
The First Affiliated Hospital of Zhengzhou University
Phase NA Unknown